AMicale des COXiens

Forum des actionnaires particuliers de NicOx
 
AccueilAccueil  GalerieGalerie  S'enregistrerS'enregistrer  ConnexionConnexion  

Partagez | 
 

 NEWS Vesneo

Voir le sujet précédent Voir le sujet suivant Aller en bas 
AuteurMessage
milpo



Nombre de messages : 23
Date d'inscription : 19/05/2014

MessageSujet: NEWS Vesneo   Dim 1 Mar - 2:28

http://www.alertetrading.com/vesneo-de-nicox-american-glaucoma-society-2015/


Vesneo de Nicox & American Glaucoma Society 2015

Auteur Publié par Webmaster Commentaires Aucun commentaire

americanglaucomasociety



Lors de l’American Glaucoma Society 2015, le docteur Liu a présenté les dernières avancées concernant les recherches sur bunod latanoprostene (VESNEO). Bien que ces résultats soient très prometteurs, ils doivent encore être finalisés et validés. Le docteur Liu indique qu’un essai clinique de plus grande envergure est actuellement en cours.

Si les données venaient à se confirmer, il semblerait que le Vesneo se révèle supérieur à celui du traitement de comparaison, la différence étant semble-t-il statistiquement significative.

Pour rappel : En septembre 2014, Bausch + Lomb et Nicox ont annoncé les premiers résultats positifs obtenus dans les études pivotales de phase 3 conduites avec VESNEO. Ces études ont atteint leur critère d’évaluation principal d’efficacité et ont montré des résultats positifs sur plusieurs critères d’évaluation secondaires. Les pics de ventes de ce médicament pourraient atteindre environ 500 millions de dollars aux États-Unis et environ 1 milliard de dollars à l’échelle mondiale.

Bausch + Lomb prévoit de soumettre un dossier de demande d’autorisation de mise sur le marché (New Drug Application, NDA) pour VESNEO auprès de la FDA américaine (Food and Drug Administration) mi-2015. Le lancement du produit pourrait intervenir au cours du premier semestre 2016, sous réserve d’approbation de la FDA.

Affaire à suivre !

Source de l’information : Latanoprostene Beats Timolol for Ocular Perfusion Pressure (Laird Harrison – February 27, 2015)

« CORONADO, California — In patients with open-angle glaucoma, the experimental drug latanoprostene bunod improves ocular perfusion pressure more than the beta-blocker timolol maleate, and fewer doses are required, according to a new study.

Latanoprostene is « much better than beta blockers, but whether it’s better than other prostaglandins » is not clear from these data, said study investigator John Liu, PhD, from the University of California at San Diego.

Dr Liu presented the findings here at the American Glaucoma Society 2015 Annual Meeting.

Latanoprostene bunod is a novel nitric-oxide-donating prostaglandin F₂-alpha analog. It is rapidly metabolized in situ to latanoprost acid and butanediol mononitrate.

Nicox and Bausch & Lomb are conducting research on latanoprostene bunod. The companies hope to market the agent as Vesneo for the treatment for intraocular pressure in open-angle glaucoma.

Last September, the companies announced that their phase 3 studies demonstrated that latanoprostene reduced intraocular pressure during both the day and night, whereas timolol only reduced it at night.

In their study, Dr Liu’s team looked at the effect of latanoprostene on ocular perfusion pressure. Previous studies have suggested that ocular perfusion pressure is a risk factor for glaucoma progression because it causes hypoperfusion of the optic nerve head.

Sitting ocular perfusion pressure was calculated as 95/140 times the mean blood pressure minus intraocular pressure. Supine pressure was calculated as 115/130 times the mean blood pressure minus intraocular pressure.

In the 25 patients with open-angle glaucoma or ocular hypertension, intraocular pressure was at least 22 mm Hg in one eye, and at least 36 mm Hg in both eyes.

Patients were randomly assigned to 4 weeks of treatment with one drop of 0.024% latanoprostene ophthalmic solution each evening at 8:00 or timolol 0.5% twice a day.

The patients then switched treatments and continued on the other study drug for another 4 weeks.

Of the 25 patients, one discontinued because of an adverse reaction, two withdrew their consent, and one was lost to follow-up.

During the latanoprostene phase, the mean increase from baseline in daytime sitting ocular perfusion pressure was 3.8 mm Hg (P < .01) and in nighttime supine pressure was 2.2 mm Hg (P < .01).

During the timolol phase, the mean increase from baseline in daytime sitting pressure was 2.0 mm Hg, the mean increase in daytime supine pressure was 2.2 mm Hg, and the mean decrease in nighttime supine pressure was –1.3 mm Hg.

The difference in the change from baseline between latanoprostene and timolol was significant for daytime sitting and nighttime supine pressure (P ≤ .02).

Although these findings are promising, they need to be validated, said Dr Liu. A larger clinical trial of these effects is underway, he reported.

Getting the same or better effects from fewer doses of medication could help glaucoma patients a lot, said Robert Stamper, MD, from the University of California at San Francisco, who was not involved in the study.

« If the data hold, it looks like it’s a slightly more powerful medication, » Dr Stamper told Medscape Medical News. For some patients, latanoprostene could make the difference « between taking a medication that they are more likely to adhere to and one they are less likely to adhere to. »

This study was funded by Bausch & Lomb. Dr Liu has disclosed no relevant financial relationships. Dr Stamper reports that he is principal investigator of a study of a drug made by Aerie Pharmaceuticals. »

American Glaucoma Society (AGS) 2015 Annual Meeting: Abstract 15. Presented February 26, 2015.

http://www.medscape.com/viewarticle/840657

Les performances passées ne préjugent pas des performances futures. Les analyses et les articles ne constituent qu’une aide à la décision pour les investisseurs. Elles ne constituent pas un conseil d’investissement au sens du Code Monétaire et Financier et du règlement général de l’Autorité des Marchés Financiers.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
milpo



Nombre de messages : 23
Date d'inscription : 19/05/2014

MessageSujet: Re: NEWS Vesneo   Lun 16 Mar - 5:54

En date du 4 mars :-)

http://www.drugs.com/cdi/latanoprost-drops.html
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
milpo



Nombre de messages : 23
Date d'inscription : 19/05/2014

MessageSujet: Re: NEWS Vesneo   Lun 16 Mar - 5:54

Latanoprost drops Pronunciation
Generic Name: latanoprost (la-TAN-oh-prost)
Brand Name: Xalatan

OverviewSide EffectsDosageInteractionsFor ProfessionalsMore
Latanoprost drops is used for:

Treating increased pressure in the eye (ocular hypertension) and open-angle glaucoma.

Latanoprost drops is a prostaglandin analog. It works to lower pressure in the eye by increasing fluid drainage from the eye.

Do NOT use latanoprost drops if:

you are allergic to any ingredient in latanoprost drops
you have a herpes infection of the eye
you are using another medicine like this one (eg, bimatoprost)
Contact your doctor or health care provider right away if any of these apply to you.

Slideshow: Easy On The Eye - 8 Tips for Maintaining Good Eyesight
Easy On The Eye - 8 Tips for Maintaining Good Eyesight
Before using latanoprost drops:

Some medical conditions may interact with latanoprost drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding
if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
if you have allergies to medicines, foods, or other substances
if you have swelling, infection, or injury of the eye
if you have a history of inflammation in the eye (eg, iritis, uveitis) or a herpes infection of the eye
if you do not have a lens in your eye or have had the lens in your eye replaced
if you have other types of glaucoma (eg, narrow-angle, neovascular)
if you will be having eye surgery
Some MEDICINES MAY INTERACT with latanoprost drops. However, no specific interactions with latanoprost drops are known at this time.

Ask your health care provider if latanoprost drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use latanoprost drops:

Use latanoprost drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Use latanoprost drops in the evening unless your doctor tells you otherwise.
Soft contact lenses may absorb a chemical in latanoprost drops. Remove contact lenses before you use latanoprost drops; lenses may be placed back in the eyes 15 minutes after use of latanoprost drops.
Wash your hands before and after using latanoprost drops.
Tilt your head back. Using your index finger, pull the lower eyelid away from the eye to form a pouch. Drop the medicine into the pouch and gently close your eyes. Immediately use your finger to apply pressure to the inside corner of the eyelid for 1 to 2 minutes. Do not blink. Remove excess medicine around your eye with a clean, dry tissue, being careful not to touch your eye. Wash your hands to remove any medicine that may be on them.
To prevent germs from contaminating your medicine, do not touch the applicator tip to any surface, including the eye. Keep the container tightly closed.
Use latanoprost drops at least 5 minutes apart from any other medicine that you put in your eye, especially eye drops that contain thimerosal.
Continue to use latanoprost drops even if you feel well. Do not miss any doses.
If you miss a dose of latanoprost drops, skip the missed dose and go back to your regular dosing schedule. Do not use 2 doses at once.
Ask your health care provider any questions you may have about how to use latanoprost drops.

Important safety information:

Latanoprost drops is for use in the eye only. Do not get it in your nose or mouth.
Latanoprost drops may cause blurred vision or make your eyes more sensitive to light. Use latanoprost drops with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it. If your eyes become sensitive to light, wearing sunglasses may help.
Latanoprost drops may cause the colored part of your eye (iris) to turn brown. This change may be permanent. It may not be noticeable for several months to years. If it occurs, you will need to have regular eye examinations. Discuss any questions or concerns with your doctor.
Latanoprost drops may cause your eyelids to darken. It may also cause changes in the way that your eyelashes grow (eg, length, thickness, number of lashes). These effects usually go away after you stop using latanoprost drops. Discuss any questions or concerns with your doctor.
Do NOT use more than the recommended dose without checking with your doctor.
Tell your doctor if you have an eye infection, eye injury, or will be having eye surgery.
You will need to have your eye pressure checked while using latanoprost drops. Be sure to keep all appointments.
PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using latanoprost drops while you are pregnant. It is not known if latanoprost drops is found in breast milk. If you are or will be breast-feeding while you use latanoprost drops, check with your doctor. Discuss any possible risks to your baby.
Possible side effects of latanoprost drops:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Blurred vision; changes in eyelash growth; cold symptoms; eye burning, dryness, itching, or stinging; feeling of having something in your eye; increased tear production.

Seek medical attention right away if any of these SEVERE side effects occur:
Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; darkening of the eyelid or eye color; eye or eyelid discharge, inflammation, irritation, pain, redness, or swelling; red, swollen, blistered, or peeling skin; vision changes.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately.

Proper storage of latanoprost drops:
Store unopened bottles in the refrigerator, between 36 and 46 degrees F (2 and 8 degrees C). Do not freeze. Opened bottles may be stored at room temperature, up to 77 degrees F (25 degrees C), for up to 6 weeks. Store away from heat, moisture, and light. Do not store in the bathroom. Keep latanoprost drops out of the reach of children and away from pets.

General information:

If you have any questions about latanoprost drops, please talk with your doctor, pharmacist, or other health care provider.
Latanoprost drops is to be used only by the patient for whom it is prescribed. Do not share it with other people.
Do not use latanoprost drops for other health conditions.
Check with your pharmacist about how to dispose of unused medicine.
This information should not be used to decide whether or not to take latanoprost drops or any other medicine. Only your health care provider has the knowledge and training to decide which medicines are right for you. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about latanoprost drops. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to latanoprost drops. This information is not specific medical advice and does not replace information you receive from your health care provider. You must talk with your healthcare provider for complete information about the risks and benefits of using latanoprost drops.

Issue Date: March 4, 2015
Database Edition 15.1.1.003
Copyright © 2015 Wolters Kluwer Health, Inc.
Revenir en haut Aller en bas
Voir le profil de l'utilisateur
Contenu sponsorisé




MessageSujet: Re: NEWS Vesneo   

Revenir en haut Aller en bas
 
NEWS Vesneo
Voir le sujet précédent Voir le sujet suivant Revenir en haut 
Page 1 sur 1
 Sujets similaires
-
» AUD/USD - News
» EUR/USD NEWS 17.02.2012
» EUR/USD NEWS 29.02.2012
» La mort des gros HYIP est maintenant inévitable.
» Loi AUBRY

Permission de ce forum:Vous ne pouvez pas répondre aux sujets dans ce forum
AMicale des COXiens :: Forum public :: Echanges sur NicOx-
Sauter vers: